Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous vs Sequential Administration of PCV13, DTaP and IIV in Young Children
NCT03165981Phase 4Completed
- Sponsor
- Duke University
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Prevnar 13, diphtheria + tetanus + acellular pertussis vaccine and Fluzone Trivalent in pneumococcal infection, diphtheria, Tetanus and 2 more (2 arms), sponsored by Duke University. Primary endpoint: Number of Participants With Fever Following Vaccination at 2 days. Started Aug 2017; status: completed.
02
Drugs
Prevnar 13diphtheria + tetanus + acellular pertussis vaccineFluzone Trivalent
03
Conditions
pneumococcal infectiondiphtheriaTetanuspertussisinfluenza
Beyond the preview
Go deeper on NCT03165981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165981.